-transparent.png){kind=logo}
The development of vectors that are capable of efficient gene delivery is crucial to the success of gene therapy. We have developed both recombinant viral and nonviral vectors with the goal of correcting genetic abnormalities in cancer cells that are responsible for malignant transformation. Infection of cancer cells by recombinant adenovirus (Adv) indicates that the level of transduction is variable and dependent on the virus-to-cell ratio. Infection of cells with Adv/p53 resulted in levels of tumor suppressor p53 gene expression that could mediate tumor cell growth suppression and apoptosis, both in vitro and in vivo. The treatment of cancer cells with cisplatin prior to Adv transduction resulted in a higher level of therapeutic gene expression. Epidermal growth factor (EGF)/DNA complexes targeted to cancer cells overexpressing the EGF receptor resulted in efficient transduction of several lung cancer cell lines in vitro. As a result, these vectors provide improved methods with which to treat cancer in the clinical setting with gene therapy.
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
April 1996,
Proceedings of the National Academy of Sciences of the United States of America,
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
February 2009,
Chemical reviews,
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
October 2007,
Die Pharmazie,
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
January 2016,
Expert opinion on biological therapy,
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
November 2012,
Cancer gene therapy,
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
January 2003,
Ernst Schering Research Foundation workshop,
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
June 2010,
Bioconjugate chemistry,
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
January 2012,
Advanced biomedical research,
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
November 2013,
Human gene therapy,
R J Cristiano, and
B Xu, and
D Nguyen, and
G Schumacher, and
M Kataoka, and
F R Spitz, and
J A Roth
October 2006,
Gene therapy,
